Brain disorders such as migraine, depression, and anxiety affect nearly half of the global population. By integrating OpenAI’s advanced AI tools into daily workflows, Lundbeck aims to free individuals and teams from repetitive tasks, allowing more time for creativity and breakthrough thinking in the pursuit of transformative treatments, the company describes in a press release. Together, the companies will explore AI-driven use cases across research, development, and commercial functions.

Integrating AI into the daily processes

Following a successful pilot, Lundbeck has already seen how ChatGPT accelerates research, streamlines analysis, and boosts quality across functions, it states. Expanding this focus on AI capabilities will for instance enable scientists, clinicians, and commercial teams to work with greater speed and creativity, the company describes further.

“By integrating AI into our daily processes, we’re unlocking new levels of efficiency and innovation, bringing science and technology together to improve outcomes for people living with brain disorders,” says Claus Thomsen, SVP, Global IT at Lundbeck.

Lundbeck has previously announced strategic partnerships with the Danish Centre for AI Innovation – focused on leveraging the Gefion AI supercomputer – and Iambic Therapeutics to advance the use of AI in drug discovery.